cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
BioRegenEx · Research

MSC Exosomes for Osteoarthritis

← Back to Research Library

Osteoarthritis (OA) is one of the most actively studied areas for MSC-derived exosomes in regenerative research. This overview is for research and educational purposes only.

What MSC exosomes are

MSC-derived exosomes are cell-free extracellular vesicles (roughly 30–150 nm) carrying signaling cargo such as proteins, lipids, and microRNA. They are supplied by BioRegenEx as characterized, research-use-only material with per-lot documentation.

What the research explores

In preclinical OA models, MSC-derived exosomes have been studied for signaling related to chondrocyte biology, cartilage matrix, and joint inflammation. These are research findings only. Explore the studies in our Exosome Research Library under Osteoarthritis and Orthopedic & Cartilage.

Sourcing considerations

For research use, look for characterized lots (particle size and concentration), sterility and endotoxin screening, cold-chain handling, and clear research-use-only labeling. Read our orthopedic sourcing guide.

Frequently Asked Questions

Are MSC exosomes an approved osteoarthritis treatment?

No. They are not FDA-approved to treat OA or any condition and are supplied for research use only (RUO).

How are exosomes studied for joints?

Preclinical research examines signaling involved in cartilage and joint biology, often in intra-articular models.

For research and educational purposes; research-use-only.

These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.